Sign in
CompletedEarly phase 1

Immunogenicity of COVID-19 Vaccine Co-administration With Influenza Vaccine in Healthy Volunteers

Key facts

Who runs it
Prince of Songkla University
Where
Thailand1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Early phase 1
People taking part
36 people enrolled
Started
1 Mar 2024
Ended
31 May 2024
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Bivalent mRNA SARS-CoV-2 vaccine
  • Quardrivalent influenza vaccine
Record updated
4 December 2025

Who can take part

Age
18 years to 60 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Thai adults aged 18-60 years, who have vaccinated COVID-19 and influenza vaccine more than 6 months
  • The subjects are able to and willing to comply with the requirements of the clinical trial program and could complete the 1-month follow-up of the study
  • Individuals who are in good health condition at the time of entry into the trial as determined by medical history, physical examination and clinical judgment of the investigator and meet the requirements of immunization
  • The subject can provide with informed consent and sign informed consent form (ICF)

Who cannot take part

  • Have the history of urticaria 1 year before receiving the investigational vaccine
  • Have received blood products within 4 months before injection of investigational vaccines
  • Have history of influenza or COVID-19 infection within 6 months
  • Have the medical history or family history of convulsion, epilepsy, encephalopathy, and psychosis
  • Be allergic to any component of the research vaccines or used to have a history of hypersensitivity or serious reactions to vaccination
  • History of Guillain-Barré syndrome
  • Have infectious diseases, including HIV and SARS-CoV-2 infection or any symptom of common cold
  • Have history of SARS-CoV-2 infection less than 6 months
  • Having severe chronic diseases or condition in progress cannot be controlled. For example, poor controlled DM and uncontrolled HT
  • Have known underlying diseases of thrombocytopenia or other coagulation disorders (which may cause contraindications for intramuscular injection)
  • Have the history of immunosuppressive therapy, cytotoxic therapy, or systemic corticosteroids
  • Under anti-tuberculosis treatment
  • Not be able to follow the protocol, or not be able to understand the informed consent according to the researcher's judgment, due to various medical, psychological, social, or other conditions
  • Women with positive urine pregnancy test, pregnant or breast-feeding, or have a pregnancy plan within six months of after baseline period
  • Having needle sickness

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study, a pilot randomized controlled trial, single-blind (outcome assessor), evaluating the immune response (both humoral and cell-mediated) against SARS-CoV-2 and the safety of three different vaccine administration approaches: the SARS-CoV-2 mRNA vaccine alone, the influenza vaccine alone, and the co-administration of both vaccines.

The 3 groups in the trial

  • Bivalent mRNA BNT162b2Existing treatment, for comparison

    Administering a booster dose of the bivalent mRNA vaccine BNT162b2.

    Treatment: Bivalent mRNA SARS-CoV-2 vaccine

  • Quardrivalent influenza vaccineTreatment being tested

    Administering a VaxigripTetra™

  • Co-administrationTreatment being tested

    Co-administering bivalent mRNA vaccine BNT162b2 and VaxigripTetra™

    Treatment: Bivalent mRNA SARS-CoV-2 vaccine and Quardrivalent influenza vaccine

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Immunogenicity to SARS-CoV-2 of Co-administering Bivalent mRNA BNT162b2 Booster and Quadrivalent Influenza Vaccine Among Healthy Volunteers: A Pilot Study
Record updated
4 December 2025